Patent for artificial pancreas developer:
This article was originally published in Clinica
Executive Summary
Ixion Biotechnology has received a US patent covering a technique for growing insulin-producing islet cells in vivo as a long-term treatment for type I diabetes. The Alachua, Florida-based company, which earlier this year became the first US biotechnology firm to launch a public offering on the Internet, is also developing tests and treatments for cystic fibrosis, renal failure, Crohn's disease and other disorders.